The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL(T315I) and exhibits a narrow resistance profile

Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABL(T315I) mutant is highly resistant to imatinib, nilotinib, and dasatinib and is frequently detected in relapsed pa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Eide, Christopher A., Adrian, Lauren T., Tyner, Jeffrey W., Mac Partlin, Mary, Anderson, David J., Wise, Scott C., Smith, Bryan, Petillo, Peter A., Flynn, Daniel L., Deininger, Michael W.N., O’Hare, Thomas, Druker, Brian J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3206627/
https://ncbi.nlm.nih.gov/pubmed/21505103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-3224
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia